SiSaf’s Innovative RNA Therapeutic for Rare Genetic Skeletal Disorders Begins the U.S. Regulatory…
SiSaf Ltd, an RNA delivery and therapeutics company, announces that it is initiating the U.S. FDA Regulatory process to obtain an Orphan Drug Designation for SIS-101-ADO, a siRNA…
Read More...
Read More...
